Predictive value of CD73 expression in EGFR-mutation positive non-small-cell lung cancer patients received immune checkpoint inhibitors.

被引：7
|
作者：
Ishii, Hidenobu
Azuma, Koichi
Kinoshita, Takashi
Matsuo, Norikazu
Naito, Yoshiko
Tokito, Takaaki
Yamada, Kazuhiko
Hoshino, Tomoaki
机构：
[1] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan
[2] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9065
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
    Ishii, Hidenobu
    Azuma, Koichi
    Kawahara, Akihiko
    Kinoshita, Takashi
    Matsuo, Norikazu
    Naito, Yoshiko
    Tokito, Takaaki
    Yamada, Kazuhiko
    Akiba, Jun
    Hoshino, Tomoaki
    [J]. THORACIC CANCER, 2020, 11 (04) : 950 - 955
  • [2] Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
    Carlisle, Jennifer W.
    Ramalingam, Suresh S.
    [J]. FUTURE ONCOLOGY, 2019, 15 (08) : 805 - 816
  • [3] Clinical Outcome and Toxicity Profiles of Patients with EGFR-mutation Positive Non-Small-Cell Lung Cancer
    Munawar, K.
    Sheikh, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S621 - S622
  • [4] EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer
    Fruh, M.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1190 - 1192
  • [5] The predictive value of uncommon EGFR mutation in patients with non-small-cell lung cancer.
    Tu, Haiyan
    Ke, Ee
    Sun, Yue-Li
    Zheng, Ming-Ying
    Yang, Jin-Ji
    Wang, Zhen
    Wu, Si-Pei
    Su, Jian
    Zhang, Xuchao
    Bai, Xiao-Yan
    Yang, Xue-Ning
    Zhong, Wenzhao
    Yan, Hong-Hong
    Zhou, Qing
    Wu, Yi-Long
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer
    Prelaj, Arsela
    Tay, Rebecca
    Ferrara, Roberto
    Chaput, Nathalie
    Besse, Benjamin
    Califano, Raffaele
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 106 : 144 - 159
  • [7] Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer
    Henriques, Geane Tomaides
    de Souza, Cleide Barbieri
    Aguiar, Pedro Nazareth, Jr.
    [J]. IMMUNOTHERAPY, 2022, 14 (04) : 249 - 257
  • [8] Prognostic impact of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Kim, Hyo Jung
    Kim, Jung Han
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [9] Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression
    Hosomi, Yukio
    Tanai, Chiharu
    Yoh, Kiyotaka
    Goto, Yasushi
    Sakai, Hiroshi
    Kato, Terufumi
    Kaburagi, Takayuki
    Nishio, Makoto
    Kim, Young Hak
    Inoue, Akira
    Hasegawa, Yoshinori
    Isobe, Hiroshi
    Tomizawa, Yoshio
    Mori, Yoshiaki
    Minato, Koichi
    Yamada, Kazuhiko
    Ohashi, Yasuo
    Kunitoh, Hideo
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (10) : 1049 - 1056
  • [10] Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer
    Fuschillo, Salvatore
    Battiloro, Ciro
    Rocco, Danilo
    D Gravara, Luigi
    Motta, Andrea
    Maniscalco, Mauro
    [J]. BIOMARKERS IN MEDICINE, 2020, 14 (11) : 929 - 932
12345